© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
May 11, 2022
In this installment of Clinical Quandaries, Justine Panian, BS, and colleagues present a case of a 60-year-old Mexican woman with fevers, abdominal pain, and hypertension.
May 02, 2022
Brian Rini, MD, summarizes the thoughts of his colleagues on the use of lenvatinib plus pembrolizumab to treat advanced renal cell carcinoma.
A panel of oncologists look at what’s in the pipeline for advanced renal cell carcinoma, including trials and treatment options.
Two kidney cancer experts explore the current unmet needs for patients with advanced renal cell carcinoma.
April 21, 2022
A look at the current unmet needs in front-line renal cell carcinoma treatment.
Oncologists review quality of life data for patients with renal cell carcinoma receiving lenvatinib plus pembrolizumab combination treatments.
April 19, 2022
Kidney cancer experts explain how they dose lenvatinib in advanced renal cell carcinoma treatment to mitigate toxicities.
An explanation of dosing strategies when treating patients with renal cell carcinoma in the first-line with lenvatinib.
Experts discuss the safety of treating renal cell carcinoma with lenvatinib within different patient risk populations.
Possible comorbidities and other risk factors in advanced renal cell carcinoma that would affect potential treatment regimens.